ClearPoint Neuro Inc vs Marvell Technology Inc — how do they compare? ClearPoint Neuro Inc trades at $15.13 (market cap $454.21M), while Marvell Technology Inc trades at $217.35 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 419.5× ClearPoint Neuro Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MRVL | |
|---|---|---|
Market Cap | $454.21M | $190.56B |
Sector | Health | Technology |
52-Week High | $29.60 | $316.43 |
52-Week Low | $8.66 | $62.31 |
Enterprise Value | $488.79M | $191.99B |
Dividend Yield | — | 0.11% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Marvell Technology (MRVL) trades at $221.86, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and revenue growth to $5.77 billion in 2025. Analyst consensus remains strongly bullish with 82% buy ratings and a $275.68 price target, representing 24% upside potential. Recent news highlights Marvell's positioning in AI infrastructure and optical networking leadership.
Marvell presents significant growth potential driven by AI data center expansion and custom chip programs with Microsoft and NVIDIA. However, investors face risks from premium valuations (P/E 72.96), supply chain constraints, and competitive pressure from Broadcom and AMD. The stock's recent volatility and high beta characteristics require careful risk management despite strong institutional support.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →